• SPX
  • $5,769.29
  • 0.99 %
  • $56.60
  • DJI
  • $42,119.44
  • 0.78 %
  • $324.83
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,175.26
  • -0.11 %
  • -$8.98
  • IXIC
  • $18,406.86
  • 1.25 %
  • $226.88
Cullinan Oncology, Inc. (CGEM) Stock Price, News & Analysis

Cullinan Oncology, Inc. (CGEM) Stock Price, News & Analysis

Currency in USD Disclaimer

$15.76

-$0.17

(-1.04%)

Day's range
$15.15
Day's range
$16.01
50-day range
$14.86
Day's range
$19.89
  • Country: US
  • ISIN: US2300311063
52 wk range
$7.64
Day's range
$30.19


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 21.65
  • Piotroski Score 3.00
  • Grade Outperform
  • Symbol (CGEM)
  • Company Cullinan Oncology, Inc.
  • Price $15.76
  • Changes Percentage (-1.04%)
  • Change -$0.17
  • Day Low $15.15
  • Day High $16.01
  • Year High $30.19

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $30.00
  • High Stock Price Target $38.00
  • Low Stock Price Target $28.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.13
  • Trailing P/E Ratio -7.16
  • Forward P/E Ratio -7.16
  • P/E Growth -7.16
  • Net Income $-153,162,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.